Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treatment for rare liver disease increases mortality risk

24.08.2005


Patients with primary biliary cirrhosis who are treated with methotrexate have an increased risk of death, according to a new systematic review of studies.

In five randomized controlled trials involving 457 people, the authors report that for patients treated with methotrexate, as a single therapy or in combination with other drug treatment, pooled data showed a tendency toward an increased risk of death or liver transplantation. The brand names for methotrexate are Rheumatrex and Trexall.

“ We do not advocate the use of methotrexate for patients with primary biliary cirrhosis,” conclude lead investigator Yan Gong, M.D., of Copenhagen University Hospital in Denmark and colleagues.


Their review appears in the latest issue of The Cochrane Library, a publication of the Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The reviewers highlight the mortality and liver transplantation data from one long-term trial in which 11 of 30 patients in the methotrexate group died or underwent liver transplantation, compared with 7 of 30 patients in the placebo group. Combining data from this and another trial other showed that “…methotrexate had a significantly detrimental effect on mortality.”

Methotrexate works by blocking metabolism of cells and is effective in treating certain diseases characterized by abnormal cell growth, like breast cancer and psoriasis. Methotrexate is also widely used to treat rheumatoid arthritis.

Many drugs have been used to treat primary biliary cirrhosis, with ursodeoxycholic acid (a bile acid) the most frequently used. In contrast to methotrexate, the reviewers note that they saw no “significant effect of ursodeoxycholic acid on mortality or liver transplantation.”

Three of the trials compared the therapeutic use of ursodeoxycholic acid with and without methotrexate. One trial compared methotrexate to colchicine.

Primary biliary cirrhosis is an uncommon liver disease, and its cause is unknown, although it may be an autoimmune disease. Ninety percent of patients are women and most are diagnosed after the age of 40. It can be a precursor to cirrhosis of the liver or liver failure.

Studies over the past 30 years indicate an increasing prevalence of the disease, but little progress has been made in slowing disease progression. Primary biliary cirrhosis has become a frequent cause of liver morbidity, and patients with this condition are increasingly undergoing liver transplantation.

The Cochrane reviewers note that their conclusions could be qualified by the size of the data pool and the mixed quality of the studies involved. “Although the majority of the evidence did not point to a beneficial effect of methotrexate for patients with primary biliary cirrhosis,” they write, “we were not able to exclude the possibility for a beneficial effect in certain patient groups. We advise that any new placebo-controlled trials with methotrexate for patients with primary biliary cirrhosis should monitor harmful effects closely.

Keith Lindor, M.D., professor of medicine at the Mayo Medical School, says, “The most important finding in this review of the research is that methotrexate may indeed be harmful in the treatment of primary biliary cirrhosis. The drug should not be used outside of clinical trials, which will not likely be done with this drug because of the lack of efficacy and potential harm.”

Gong Y, Gluud C. Methotrexate for primary biliary cirrhosis. The Cochrane Database of Systematic Reviews 2005, Issue 3.

Yan Gong | EurekAlert!
Further information:
http://www.cfah.org

More articles from Health and Medicine:

nachricht Penn studies find promise for innovations in liquid biopsies
30.03.2017 | University of Pennsylvania School of Medicine

nachricht 'On-off switch' brings researchers a step closer to potential HIV vaccine
30.03.2017 | University of Nebraska-Lincoln

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

'On-off switch' brings researchers a step closer to potential HIV vaccine

30.03.2017 | Health and Medicine

Penn studies find promise for innovations in liquid biopsies

30.03.2017 | Health and Medicine

An LED-based device for imaging radiation induced skin damage

30.03.2017 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>